keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/29774076/the-human-somatostatin-receptor-type-2-as-an-imaging-and-suicide-reporter-gene-for-pluripotent-stem-cell-derived-therapy-of-myocardial-infarction
#1
Katrien Neyrinck, Natacha Breuls, Bryan Holvoet, Wouter Oosterlinck, Esther Wolfs, Hubert Vanbilloen, Olivier Gheysens, Robin Duelen, Willy Gsell, Ivo Lambrichts, Uwe Himmelreich, Catherine M Verfaillie, Maurilio Sampaolesi, Christophe M Deroose
Rationale: Pluripotent stem cells (PSCs) are being investigated as a cell source for regenerative medicine since they provide an infinitive pool of cells that are able to differentiate towards every cell type of the body. One possible therapeutic application involves the use of these cells to treat myocardial infarction (MI), a condition where billions of cardiomyocytes (CMs) are lost. Although several protocols have been developed to differentiate PSCs towards CMs, none of these provide a completely pure population, thereby still posing a risk for neoplastic teratoma formation...
2018: Theranostics
https://www.readbyqxmd.com/read/29762236/acute-pancreatitis-following-peptide-receptor-radionuclide-therapy-an-unusual-adverse-event
#2
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29747035/microscale-radiosynthesis-preclinical-imaging-and-dosimetry-study-of-18-f-ambf-3-tate-a-potential-pet-tracer-for-clinical-imaging-of-somatostatin-receptors
#3
Ksenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, Andreea D Stuparu, Seval Beykan, Jeffrey Collins, Jason Jones, Michael Lassmann, Ken Herrmann, David Perrin, Jason T Lee, Roger Slavik, R Michael van Dam
BACKGROUND: Peptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging...
April 20, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29741215/role-of-dotatate-pet-ct-in-preoperative-assessment-of-phaeochromocytoma-and-paragangliomas
#4
Matti L Gild, Nikita Naik, Jeremy Hoang, Edward Hsiao, Rachel T McGrath, Mark Sywak, Stan Sidhu, Leigh Walter Delbridge, Bruce Gregory Robinson, Geoff Schembri, Roderick John Clifton-Bligh
CONTEXT: Diagnosis of paragangliomas (PGL) and phaeochromocytomas (PC) can be challenging particularly if the tumour is small. Detection of metastatic disease is important for comprehensive management of malignant PC/PGL. Somatostatin receptor imaging (SRI) agents have high sensitivity for these tumours, particularly the DOTA family of radiopharmaceuticals labelled with 68 Gallium. OBJECTIVE: To describe the utility of SRI in primary assessment (i.e. before surgery) for PC/PGL and whether measures of maximum standardized uptake (SUVmax) could be used to distinguish between adrenal adenomas and PCs...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29741203/peptide-receptor-radionuclide-therapy-for-advanced-gastroenteropancreatic-neuroendocrine-tumors-from-oncology-perspective
#5
Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system)...
2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29736841/evaluation-of-the-interaction-of-amino-acid-infusion-on-177-lu-dotatate-pharmacokinetics-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors
#6
Alicja Puszkiel, Mathilde Bauriaud-Mallet, Roxane Bourgeois, Lawrence Dierickx, Frédéric Courbon, Etienne Chatelut
BACKGROUND AND OBJECTIVE: 177 Lu-Dotatate is a radio-labeled analog of somatostatin used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. In order to prevent nephrotoxic effects of 177 Lu-Dotatate a co-infusion of amino acids (AA) is administered, resulting in a decrease in tubular renal reabsorption of 177 Lu-Dotatate. This study aimed to quantify the impact of AA co-infusion on the pharmacokinetics of 177 Lu-Dotatate in cancer patients and to evaluate its relationship with toxicity during the first treatment cycle (C1)...
May 8, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29724807/rapid-itlc-system-for-determining-the-radiochemical-purity-of-68-ga-dotatate
#7
Michael Bornholdt, Kayla Woelfel, Ping Fang, Mark Jacobson, Joseph Hung
The objective of this study was to develop instant thin layer chromatography (ITLC) conditions for the determination of radiochemical purity (RCP) of 68 Ga-DOTATATE in a shorter time period than those stated in the NETSPOT (Advanced Accelerator Applications, Saint-Genis-Pouilly, France; AAA) kit package insert (PI). A faster ITLC system is needed to reduce the current 48-50 minutes development time; so that (1) more radioactivity is available for single patient use as the generator ages and (2) wait times are shorter in the event of kit failure...
May 3, 2018: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/29719482/first-results-and-experience-with-prrt-in-south-africa
#8
Mariza Vorster, M R Modiselle, C S Corbett, I O Lawal, John R Buscombe, Mike M Sathekge
Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs), which allows for positron emission tomography/computed tomography (PET/CT) imaging with Ga-68-DOTATATE. In eligible patients, this may then be followed by peptide receptor radionuclide therapy (PRRT). Here, we report our initial results and experience with PRRT in a developing country, as one of the first groups to provide this therapy in South Africa...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29717082/aetna-and-68-ga-dotatate-a-sequel-to-the-injustice-of-being-judged-by-the-errors-of-others
#9
EDITORIAL
Johannes Czernin, Francesco Ceci
No abstract text is available yet for this article.
May 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29688946/lung-metastases-of-intracranial-atypical-meningioma-diagnosed-on-posttherapeutic-imaging-after-177lu-dotatate-therapy
#10
Philipp Backhaus, Sebastian Huss, Volkan Kösek, Matthias Weckesser, Kambiz Rahbar
Meningiomas are typically benign solitary intracranial tumors. Atypical (World Health Organization [WHO] grade II) or malignant/anaplastic (WHO grade III) meningiomas are seldom, and distant metastases occur only in rare exceptions. We present a case of a 54-year-old male patient with atypical (WHO grade II) meningioma who underwent 1 cycle of peptide receptor radionuclide therapy. Previous imaging studies were confined to the head, but posttherapeutic whole-body Lu-DOTATATE scintigraphy revealed thoracic uptake arising from previously undetected pulmonic meningioma metastases...
June 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29687322/optimization-of-a-labeling-and-kit-preparation-method-for-ga-68-labeled-dotatate-using-cation-exchange-resin-purified-ga-68-eluates-obtained-from-a-tin-dioxide-68-ge-68-ga-generator
#11
Deidré Prince, Daniel Rossouw, Sietske Rubow
PURPOSE: The aim of this study was to optimize a radiolabeling method using cationic processed Ga-68 eluates from a SnO2 -based 68 Ge/68 Ga generator, followed by the development of DOTA-Tyr3 -Thre8 -octreotide (DOTATATE) kits. PROCEDURES: Diluted generator eluates were adsorbed on a SCX resin and desorbed with acidified 5 M NaCl solution. Optimized labeling conditions were determined by variation of pH, using 35 μg DOTATATE and sodium acetate buffer. DOTATATE kits were developed based on optimized radiolabeling conditions, were labeled, and evaluated...
April 23, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29681780/clinical-and-prognostic-value-of-pet-ct-imaging-with-combination-of-68-ga-dotatate-and-18-f-fdg-in-gastroenteropancreatic-neuroendocrine-neoplasms
#12
Panpan Zhang, Jiangyuan Yu, Jie Li, Lin Shen, Nan Li, Hua Zhu, Shizhen Zhai, Yan Zhang, Zhi Yang, Ming Lu
Background: To evaluate the clinical and prognostic value of PET/CT with combination of 68 Ga-DOTATATE and 18 F-FDG in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Method: 83 patients of GEP-NENs who underwent 68 Ga-DOTATATE and 18 F-FDG PET/CT were enrolled between June 2013 and December 2016. Well-differentiated (WD) NETs are divided into group A (Ki-67 < 10%) and group B (Ki-67 ≥ 10%), and poorly differentiated (PD) NECs are defined as group C...
2018: Contrast Media & Molecular Imaging
https://www.readbyqxmd.com/read/29662560/impact-of-68-ga-dota-peptide-pet-ct-on-the-management-of-gastrointestinal-neuroendocrine-tumour-gi-net-malaysian-national-referral-centre-experience
#13
Teik Hin Tan, Ching Yeen Boey, Boon Nang Lee
Purpose: The National Cancer Institute is the only referral centre in Malaysia that provides 68 Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of 68 Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET). Materials and Methods: A cross-sectional study was performed to review the impact of 68 Ga-DOTA-peptide (68 Ga-DOTATATE or 68 Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29622939/pharmaceutical-approval-update
#14
Mary Choy
Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors.
April 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/29543624/effect-of-thyroid-stimulating-hormone-in-68ga-dotatate-pet-ct-of-radioiodine-refractory-thyroid-carcinoma-a-pilot-study
#15
Ludmila S Almeida, Maidane C Araújo, Denise E Zantut-Wittmann, Lígia V Assumpção, Thiago F Souza, Cleide M Silva, Juliana L Argenton, Allan O Santos, Jair Mengatti, Celso D Ramos, Elba C Etchebehere
BACKGROUND: Radioiodine-refractory thyroid carcinomas (RAIRs) are characterized by reduced expression of sodium-iodine symporter, rising serum thyroglobulin levels, and negative whole-body radioiodine scans. Interestingly, RAIRs continue to express somatostatin receptors and can be identified with Ga-DOTATATE PET/CT imaging. OBJECTIVE: The objective of this study was to compare lesion detectability in Ga-DOTATATE PET/CT performed with elevated thyroid-stimulating hormone (eTSH) levels with suppressed thyroid-stimulating hormone (sTSH) levels...
May 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29536494/-somatostatin-receptor-pet-ct-sstr-pet-ct
#16
C Boy, T Poeppel, J Kotzerke, B J Krause, H Amthauer, R P Baum, I Buchmann, S Ezziddin, D Führer, M Gabriel, T Kuwert, H Lahner, T Lauenstein, H R Maecke, J Nagarajah, F Rösch, K Scheidhauer, M Schmidt, M A Walter, A Bockisch
The present guideline is focused on quality assurance of somatostatin receptor PET/CT (SSTR-PET/CT) in oncology patients. The document has been developed by a multidisciplinary board of specialists providing consensus of definitions, prerequisites, methodology, operating procedures, assessment, and standardized reporting. In particular, imaging procedures for the two most commonly used radioligands of human SSTR, i. e. 68Ga-DOTATOC and 68Ga-DOTATATE are presented. Overall, SSTR-PET/CT requires close interdisciplinary communication and cooperation of referring and executing medical disciplines, taking into account existing guidelines and recommendations of the European and German medical societies, including the European Association of Nuclear Medicine (EANM), German Society for Endocrinology (DGE), German Society for Nuclear Medicine (DGN) and German Society for Radiology (DRG)...
February 2018: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/29534198/18f-fdopa-pet-ct-imaging-of-max-related-pheochromocytoma
#17
David Taïeb, Abhishek Jha, Carole Guerin, Ying Pang, Karen T Adams, Clara C Chen, Pauline Romanet, Philippe Roche, Wassim Essamet, Alexander Ling, Martha M Quezado, Frédéric Castinetti, Fréderic Sebag, Karel Pacak
Context: MYC associated factor X (MAX) has been recently described as a new susceptibility pheochromocytoma (PHEO) gene with a total of approximately 40 reported cases. At present, no study has specifically described the functional imaging phenotype of MAX-related PHEO. Objective, Patients, and Design: The objective of this study was to present our experience with contrast-enhanced CT and 18F-FDOPA PET/CT imaging in 6 consecutive patients (4 at initial diagnosis and 2 at follow-up evaluation) with rare but clinically important MAX-related PHEOs...
March 8, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29528911/the-effect-of-kidney-volume-estimation-on-dosimetry-in-lutetium-177-dotatate-therapy
#18
Lucy F Matthews, Ivor W Jones
BACKGROUND: The kidneys are the dose-limiting organ in lutetium-177 DOTATATE therapy. Therefore, it is advisable to perform critical organ dosimetry focussed on renal dose in treated patients. A key uncertainty in such dose estimates is the use of standard phantoms to represent the individual patient. The primary aim of this study was to investigate the accuracy of methods for estimating kidney size, and hence absorbed kidney dose, by comparison with individual measurements from computed tomography (CT) imaging...
March 9, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29513039/retreatment-with-peptide-receptor-radionuclide-therapy-in-patients-with-progressing-neuroendocrine-tumours-efficacy-and-prognostic-factors-for-response
#19
Emily Vaughan, Joseph Machta, Martin Walker, Christos Toumpanakis, Martyn Caplin, Shaunak Navalkissoor
OBJECTIVE: To evaluate the efficacy and toxicity of a repeat peptide receptor radionuclide therapy (PRRT) course in neuroendocrine tumour patients who have progressed following previous PRRT and to identify factors contributing to retreatment outcomes. METHODS: This was a retrospective analysis of 47 consecutive patients who had been treated with PRRT (PRRT1) and following disease progression were retreated with a second course of PRRT (PRRT2). We reviewed patient, tumour and treatment characteristics, time to progression after PRRT1 and PRRT2, overall survival and toxicity...
March 20, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29487054/lutetium-lu-177-dotatate-approved-by-fda
#20
(no author information available yet)
The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial.
April 2018: Cancer Discovery
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"